India's nutraceutical export value exceeded USD 4 billion in 2024, supported by retailers and distributors in North America, the European Union, and Gulf Cooperation Council markets. For a small supplement brand, that figure matters because it reflects a deeper pool of Indian CDMOs able to discuss export production, not just domestic supply.
How Indian manufacturing quality changed
India's nutraceutical manufacturing infrastructure has developed considerably since 2018. Two policy changes explain much of that shift. FSSAI enforcement expanded in 2022, while manufacturing expectations became more structured from 2019 onward. Together, these changes made documentation, facility controls, and batch consistency more important in supplier selection.
More pharmaceutical and supplement facilities now pursue US FDA, EU GMP, or WHO-GMP certifications alongside FSSAI approvals. A facility seeking US private-label work also needs processes aligned with 21 CFR Part 111. That does not make every supplier suitable, but it gives small brands a clearer basis for screening production partners.
The point is not that every Indian supplement facility meets export requirements. Rather, the qualified part of the market is now large enough for a small brand to identify a suitable partner without assuming that only very large manufacturers can help.
FSSAI certification and export requirements
FSSAI certification is the domestic baseline for nutraceutical and supplement manufacturing in India. It is not, by itself, sufficient for shipments to the US, EU, or UK. Those markets impose additional requirements around formulation, labeling, documentation, and facility controls. Indian CDMO production is not automatically export-compliant. FSSAI approval is a baseline; destination-market compliance requires additional steps.
For EU shipments, the relevant framework includes Regulation (EC) No 1925/2006 on adding vitamins and minerals to foods, along with general food safety requirements under Regulation (EC) No 178/2002. EU supplement buyers may also require evidence that the formula, claims, ingredients, and records fit the market in which the product will be sold.
For a small brand evaluating an Indian CDMO, ask which export-market certifications the facility holds and whether they cover the specific product and destination. A certificate on its own is less useful than certification connected to the actual production scope.
Lead times and logistics
Indian production adds transit time that domestic manufacturing may avoid. Commercial air freight from Hyderabad or Mumbai to US East Coast markets generally takes about 3 to 5 transit days, before accounting for freight booking, customs processing, and final delivery.
A practical minimum for an India-manufactured batch reaching a US customer is roughly 6 to 10 weeks. That includes 4 to 6 weeks for manufacturing and documentation, followed by 1 to 5 weeks for logistics, depending on freight and clearance conditions.
Export paperwork also goes beyond domestic shipping. A finished-goods shipment from India requires a commercial invoice, packing list, bill of lading or airway bill, Certificate of Analysis, and potentially other documents requested by the buyer or destination market.
When Indian CDMOs fit small brands
Indian CDMO production is most practical for brands with 2 characteristics: a stable formula with predictable order volumes, and a distribution channel that can absorb an 8 to 12 week replenishment cycle. It is less suitable when inventory must be replaced immediately or the formula changes with every order.
The cost gap between Indian and North American or European CDMO rates can be meaningful at small volumes. For a 500-unit capsule pilot, an Indian quote may show a 25 to 35 percent difference, while a 5,000-unit production run can make a 40 to 60 percent comparison more visible. The correct decision still depends on freight, documentation, and timing.
What this does not solve
Lower manufacturing cost does not settle regulatory compliance in the destination market. An Indian CDMO can issue a CoA and batch record, but the brand remains responsible for checking whether its label claims comply with US, EU, or UK requirements.
Leumas manufactures from HITEC City, Hyderabad, Telangana, India, for Indian domestic distribution and export-ready production runs. Our process includes the export documentation layer, including CoA, ingredient traceability, and batch records. AI-assisted batch scheduling helps us plan work across pilot and production orders, but it does not replace market-specific review.